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MENTAL HEALTH
MENTAL HEALTH—Clincal Outcomes Studies
PMH1
IMPACT OF WEIGHT GAIN ON TREATMENT EFFECTIVENESS
WITH OLANZAPINE OR ARIPIPRAZOLE, CONSIDERING NON-
ADHERENCE, RELAPSE AND COST OF RELAPSE IN PATIENTS
WITH SCHIZOPHRENIA IN FINLAND
Ruppert A1, Muhonen T2, Sinkkonen T2
1Bristol-Myers Squibb, Braine-l’Alleud, Belgium; 2Bristol-Myers Squibb,
Espoo, Finland
OBJECTIVES: Occurrence of weight gain during antipsychotic
therapy may not only lead to increased metabolic or cardiovas-
cular risks but may also inﬂuence treatment effectiveness,
reﬂected by adherence to antipsychotic therapy. Aim of this
analysis is to link weight gain during treatment with olanzapine
and aripiprazole in clinical trials to medication non-adherence
and, in consequence, to relapse and cost of relapse from a Finnish
perspective, based on comparable efﬁcacy in treating schizo-
phrenia. METHODS: In a web-based interview, 104 Finnish psy-
chiatrists described the impact of antipsychotic treatment-related
weight gain on adherence and estimated the percentage of their
patients with schizophrenia becoming non-adherent, when expe-
riencing >7% weight gain during six months of antipsychotic
treatment. The result was linked to the primary efﬁcacy outcome
measure, percentage of patients showing signiﬁcant (>7%)
weight gain, in a 26-week random clinical trial of aripiprazole
vs. olanzapine. Drug non-adherence-related relapse data and
costs of treating relapse were derived from published sources.
Cost analysis was based on Finnish payer’s perspective.
RESULTS: After 26 weeks, 33% in the olanzapine group showed
>7% weight gain, compared to 13% with aripiprazole. Finnish
psychiatrists estimated 18% of their patients becoming non-com-
pliant when experiencing >7% weight gain within 6 months of
antipsychotic therapy. The percentage of medication non-
compliant patients who experienced a relapse is 37%. Results
show a relative risk reduction estimate for relapse due to weight
gain related non-adherence of 64% with aripiprazole versus
olanzapine. When treating 1000 patients with aripiprazole
instead of olanzapine over 6 months, 14 relapses due to weight
gain related non-adherence could be avoided, with estimated cost
savings of 180,950€ due to avoided acute relapse treatment in
Finnish hospitals. CONCLUSIONS: Results highlight improved
effectiveness with medical and economic beneﬁt of aripiprazole
versus olanzapine, reﬂected by potentially reduced relapse rates
due to weight gain induced non-adherence.
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GEO OBSERVATIONAL STUDY: 12 MONTH’S DISEASE
CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC
STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH
OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann FRW1, Reitberger U1, Clouth J2, Salize HJ3
1Kendle International Inc, Munich, Germany; 2Lilly Deutschland GmbH,
Hamburg, Germany; 3Zentralinstitut für Seelische Gesundheit,
Mannheim, Germany
OBJECTIVES: To describe real life disease characteristics, side
effects and socioeconomic situations for schizophrenia inpatients
and outpatients treated with olanzapine or haloperidol over 12
months. METHODS: GEO is a German 2-year prospective nat-
uralistic observational study. Quarterly observations were made
for 289 patients included in the study under olanzapine treat-
ment and 187 patients included under haloperidol treatment.
RESULTS: During the 12 months study period, olanzapine and
haloperidol treatment was stable (olanzapine: 96% of follow up
days with study medication coverage vs. haloperidol: 94%; med-
ication or dosage changes 56% vs. 38%). General, negative and
cognitive symptoms ranged from “moderate” to “clearly ill”
(average CGI summary scores 3–4). Positive and depressive
symptoms ranged from “mild” to “moderate” (CGI 2–3).
During the course of the study, disease severity improved for all
symptoms (p < 0.05; not signiﬁcant for haloperidol positive and
depressive score) with slightly better improvement in olanzapine
patients. Throughout the study period, signiﬁcantly fewer olan-
zapine patients had extrapyramidal side effects. Average
extrapyramidal, parkinsonism, retardation and akathisia side
effects were milder in olanzapine patients. Other side effects were
reported more frequently for olanzapine (<28% vs. <8%). Con-
comitant schizophrenia-related medication was prescribed sig-
niﬁcantly less frequently for olanzapine patients (48% vs. 64%).
Compared to haloperidol patients, more patients under olanza-
pine were able to care for themselves (86% vs. 79%), lived at
home without care (58% vs. 39%), were employed (34% vs.
17%), and fewer were in early retirement (29% vs. 49%). CON-
CLUSIONS: In Germany, real life schizophrenia patients under
olanzapine treatment showed a higher degree of integration into
social and occupational environment. For olanzapine patients,
all schizophrenia symptoms signiﬁcantly improved over time.
Additionally, olanzapine patients exhibited less extrapyramidal,
parkinsonism, retardation and akathisia side-effects than
patients treated with haloperidol.
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FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED
ON RISPERIDONE OR OLANZAPINE: A TIME-TO-EVENT
ANALYSIS
Adriaenssen I1, Rosillon D2, Mehnert A3, Price M4, Ingham M1
1Janssen Pharmaceutica N.V, Beerse, Belgium; 2SGS Biopharma S.A,
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OBJECTIVES: To examine time to re-hospitalisation and re-
hospitalisation rates of patients who had been discharged from
psychiatric hospitals after starting treatment with either risperi-
done or olanzapine. METHODS: A multi-centre retrospective
cohort study was carried out in 9 centres in 3 countries. Re-
hospitalisation status was monitored in 393 schizophrenia
patients previously discharged on one of the two study drugs.
Data were collected using a pre-deﬁned; standardised data col-
lection template. The proportion of re-hospitalised patients were
compared between risperidone and olanzapine using the
Cochran-Mantel-Haenszel test stratiﬁed by centre. Time to re-
admission was assessed and compared between the two groups
of patients using Kaplan-Meier curves, log-rank test and Cox
proportional hazard models. RESULTS: Median follow up was
1282 days in the risperidone group and 1207 days in the olan-
zapine group, ranging from 93 to 2985 days across both groups.
The proportion of re-hospitalised patients was lower for patients
discharged on risperidone (59%) than for patients discharged on
olanzapine (66%) (p = 0.089). Reason for re-hospitalisation was
similar in both groups with 65% and 68% of all re-admissions
in the risperidone and olanzapine group respectively due to
relapse of schizophrenia, with 42% (192 cases) of all re-hospi-
talisations linked to non-compliance. The time to ﬁrst re-admis-
sion was longer in the risperidone group (KM median estimate:
925 days; 95%CI: 660–1249 days) than in the olanzapine group
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(526 days; 95%CI: 433–865 days). The difference was statisti-
cally signiﬁcant (p = 0.028). The overall risk of a ﬁrst re-admis-
sion was lower after discharge on risperidone than on olanzapine
(Hazard ratio: 0.71; 95% CI: 0.55–0.93). CONCLUSIONS:
Starting hospitalised acute schizophrenia patients on treatment
with risperidone rather than on olanzapine appears to have a
positive impact on time to next hospitalisation.
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THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
OR SCHIZOAFFECTIVE DISORDER IN AUSTRALIA;
A RETROSPECTIVE AUDIT
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OBJECTIVES: To quantify the costs and resource utilisation
associated with a relapse episode in patients with schizophrenia
or schizoaffective disorder. METHODS: A retrospective audit of
data from 200 patients diagnosed with schizophrenia or
schizoaffective disorder was performed. These patients accessed
both inpatient and community services from two mental health
services in Australia between June 1, 2001 and May 31, 2002.
Entry into the audit was determined by a hospitalisation due to
relapse. Data was collected for the 12 months before and 12
months after the hospitalisation. Number of contacts, type of
contact and the cost associated with these contacts were deter-
mined, together with length of stay in hospital before, after and
during the relapse episode. Costs were assigned based on the
Australian Department of Veteran Affairs data. RESULTS: Pre-
liminary data from 193 patients show that prior to hospitalisa-
tion, (mean stay 23.3 ± 26.3[SD] days) the number of contacts
per month ranged from 3.1 ± 3.7 at 12 months pre-hospitalisa-
tion to 3.6 ± 5.2 at 2 months pre-hospitalisation. The number
of contacts rose to 5.4 ± 6.6 in the month prior to hospitalisa-
tion. After hospitalisation, the average number of contacts per
month ranged from 4.6 ± 4.8 at 1 month to 4.7 ± 5.7 at 12
months post-admission. The mean stay in hospital was 23.3 ±
26.3 days. The trends for the costs associated with contacts are
consistent with the use of health care professional contacts over
the audit period. CONCLUSIONS: Increased health care
resource utilisation may be associated with relapse episodes in
patients with schizophrenia or schizoaffective disorder. Increases
in service use appear to persist across the 12 months following
the relapse episode.
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FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED
FROM PSYCHIATRIC HOSPITALS IN THE UK ON
RISPERIDONE OR OLANZAPINE: A TIME-TO-EVENT ANALYSIS
Price M1, Rosillon D2, Ingham M3,Adriaenssen I3
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OBJECTIVES: To examine time to, and rate of re-
hospitalisation of schizophrenia patients discharged from 
psychiatric hospitals while being treated with risperidone or
olanzapine. This study was carried out in nine centres across
three European countries (Germany, Netherlands and UK). In
this analysis, we present results for the 5 participating UK
centres. METHODS: Re-hospitalisation status was monitored in
196 patients previously discharged on risperidone or olanzapine
using a standardised data collection template. Time to re-
admission was compared using Kaplan-Meier curves, log-rank
test and Cox proportional hazard models. The proportion of 
re-hospitalised patients was compared using the Cochran-
Mantel-Haenszel test stratiﬁed by centre. RESULTS: In total,
119 (61%) of the 196 patients required at least one re-
hospitalisation during the evaluation period. The most common
reason for re-admission was schizophrenia relapse and readmis-
sion was speciﬁcally attributed to non-compliance in 34% of
cases. Median follow-up was 1344 days and 1115 days in the
risperidone and olanzapine groups, respectively. The KM median
estimate of time to ﬁrst re-admission was longer in the risperi-
done group (1045 days) than the olanzapine group (604 days).
The overall risk of a ﬁrst re-admission was lower after discharge
on risperidone than on olanzapine, with a strong trend to sig-
niﬁcance (Hazard ratio: 0.69; 95% CI: 0.47–1.01). Results for
the UK patients were consistent with the pooled results for the
three countries. CONCLUSIONS: In this UK follow-up study,
patients treated with and discharged on risperidone had a lower
risk of re-admission than those treated and discharged on olan-
zapine. Patients treated with risperidone had a longer median
time to ﬁrst admission than those treated with olanzapine.
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HEALTH EFFECTS AND HEALTH CARE RESOURCE
UTILIZATION IN POLISH SCHIZOPHRENIC OUTPATIENTS
INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL
ANTIPSYCHOTIC MONOTHERAPY: ANALYSIS OF 12-MONTH
DATA FROM SOHO STUDY
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OBJECTIVES: To evaluate effects and resource utilization in
outpatients with schizophrenia initiating or changing to
monotherapy antipsychotic treatment. METHODS: Data on
health effects and resource utilization were collected prospec-
tively in a multicentre observational study with a 12-month
duration. There were two cohorts: patients initiating or chang-
ing to olanzapine [O] or typical antipsychotic monotherapy [T].
The cumulative numbers of inpatient days, days in day-
hospital/day-care and outpatient consultations were calculated
per patient and per user separately. Treatment groups were com-
pared in terms of these variables using adjusted analysis. The
comparison in terms of response, relapse, worsening and mini-
mally symptomatic patients was made using logistic regression
analysis with adjustment for baseline variables. RESULTS: A
total of 344 patients were included: 254 in [O] and 90 in [T].
The baseline characteristics were comparable for both groups.
Clinical response was achieved in 53.7% and 27.5% patients in
[O] and [T] respectively; OR vs. olanzapine 0.36 (p = 0.001).
No signiﬁcant differences were detected between groups in terms
of relapses and worsened CGI score. There were more minimally
symptomatic patients in [O] (34.3%) than in [T] (19.2%). The
mean number of inpatient days was 4.96 and 6.77 per patient;
and 45.85 and 46.67 per user in [O] and [T] respectively. The
mean number of days in day-hospital/day-care per patient was
4.43, 9.3 per patient, and 57.00 and 99.17 per user in [O] and
[T] respectively. The mean number of consultations was 8.00 in
[O] and 7.5 [T]. Signiﬁcantly more patients remained on initial
drug in [O] (67.9%) than in [T] (50.7%); OR vs olanzapine 0.48;
p = 0.00113. CONCLUSIONS: This preliminary analysis show
that in group [O] in comparison to [T] a greater proportion of
patients achieved clinical response and remained on initial drug.
The health care resource utilization seems to be lower both per
patient and user in [O].
